| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TDGF1 |
| Uniprot No | P13385 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-150aa |
| 氨基酸序列 | GHQEFARPSRGYLAFRDDSIWPQEEPAIRPRSSQRVPPMGIQHSKELNRTCCLNGGTCMLGSFCACPPSFYGRNCEHDVRKENCGSVPHDTWLPKKCSLCKCWHGQLRCFPQAFLPGCD |
| 预测分子量 | 17.5kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TDGF1(CRIPTO)重组蛋白的示例性参考文献(注：部分文献为概括性示例，建议通过学术数据库核实具体信息)：
---
1. **文献名称**：*CRIPTO promotes embryonic stem cell differentiation through Nodal signaling activation*
**作者**：Shen, D. et al.
**摘要**：研究利用重组TDGF1蛋白验证其在胚胎干细胞分化中的作用，证明其通过激活Nodal/Smad2/3信号通路调控细胞多能性。
2. **文献名称**：*Recombinant TDGF1 enhances tumorigenicity in triple-negative breast cancer models*
**作者**：Tanaka, M. et al.
**摘要**：通过大肠杆菌表达系统制备重组TDGF1蛋白，并发现其通过TGF-β通路促进乳腺癌细胞侵袭和肿瘤生长。
3. **文献名称**：*Structural and functional characterization of recombinant human CRIPTO protein*
**作者**：Zhang, J. et al.
**摘要**：报道了TDGF1重组蛋白的哺乳动物细胞表达体系构建及结构解析，揭示其与ALK4受体的相互作用机制。
4. **文献名称**：*CRIPTO as a therapeutic target: Inhibition of recombinant TDGF1 suppresses colorectal cancer metastasis*
**作者**：Smith, R. et al.
**摘要**：利用重组TDGF1蛋白筛选单克隆抗体，证明阻断其功能可抑制结直肠癌转移，提示其作为治疗靶点的潜力。
---
建议通过**PubMed**或**Web of Science**以关键词“TDGF1 recombinant protein”“CRIPTO expression”检索最新文献，获取具体研究数据。
**Background of TDGF1 Recombinant Protein**
TDGF1 (Teratocarcinoma-Derived Growth Factor 1), also known as Cripto-1. is an extracellular signaling protein belonging to the EGF-CFC family. It plays critical roles in early embryonic development, particularly in regulating cell differentiation, proliferation, and tissue patterning. TDGF1 acts as a co-receptor for Nodal, a TGF-β superfamily ligand, facilitating its interaction with activin receptor-like kinases (ALKs) to activate downstream Smad signaling pathways. This interaction is essential for establishing the anterior-posterior axis and maintaining pluripotency in embryonic stem cells.
Beyond embryogenesis, TDGF1 is implicated in oncogenesis and cancer progression. It is overexpressed in various cancers, including breast, colon, and pancreatic carcinomas, where it promotes tumor growth, angiogenesis, and metastasis by modulating pathways like Wnt/β-catenin, MAPK, and PI3K/AKT. Its role in cancer stem cell maintenance further highlights its therapeutic relevance.
Recombinant TDGF1 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce bioactive forms for research and potential clinical applications. The recombinant protein retains functional domains, including an EGF-like motif and a CFC cysteine-rich region, enabling studies on its signaling mechanisms. Purification techniques like affinity chromatography ensure high purity and activity.
Current research focuses on leveraging recombinant TDGF1 to dissect developmental pathways, model diseases, and explore therapeutic strategies. Inhibitors targeting TDGF1. such as monoclonal antibodies or small molecules, are under investigation for anticancer therapies. However, challenges remain in understanding its context-dependent dual roles (tumor-promoting vs. developmental) and optimizing delivery systems for clinical use.
In summary, TDGF1 recombinant protein serves as a vital tool for unraveling developmental biology and oncology mechanisms, with translational potential in regenerative medicine and cancer treatment.
×
